1: Erratum: Systematic review and meta-analysis: bezafibrate in patients with 
primary biliary cirrhosis [Erratum]. Drug Des Devel Ther. 2015 Nov 6;9:5947. 
eCollection 2015. PubMed PMID: 26604692; PubMed Central PMCID: PMC4642802.

2: Liu X, Yang X, Chen X, Zhang Y, Pan X, Wang G, Ye Y. Expression Profiling 
Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma. J 
Cancer. 2015 Sep 20;6(12):1214-21. doi: 10.7150/jca.12191. eCollection 2015. 
PubMed PMID: 26535062; PubMed Central PMCID: PMC4622851.

3: Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H, 
Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C. Systematic review and 
meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug Des 
Devel Ther. 2015 Sep 30;9:5407-19. doi: 10.2147/DDDT.S92041. eCollection 2015. 
PubMed PMID: 26491252; PubMed Central PMCID: PMC4599574.

4: Feng Y, Wang C, Liu Q, Meng Q, Huo X, Liu Z, Sun P, Yang X, Sun H, Qin J, Liu 
K. Bezafibrate-mizoribine interaction: Involvement of organic anion transporters 
OAT1 and OAT3 in rats. Eur J Pharm Sci. 2016 Jan 1;81:119-28. doi: 
10.1016/j.ejps.2015.10.008. Epub 2015 Oct 22. PubMed PMID: 26474691.

5: Courchesne-Loyer A, St-Pierre V, Hennebelle M, Castellano CA, Fortier M, 
Tessier D, Cunnane SC. Ketogenic response to cotreatment with bezafibrate and 
medium chain triacylglycerols in healthy humans. Nutrition. 2015 
Oct;31(10):1255-9. doi: 10.1016/j.nut.2015.05.015. Epub 2015 Jun 6. PubMed PMID: 
26333891.

6: Honda A, Ikegami T, Matsuzaki Y. Anti-gp210 and anti-centromere antibodies for 
the prediction of PBC patients with an incomplete biochemical response to UDCA 
and bezafibrate. Hepatol Res. 2015 Aug;45(8):827-8. doi: 10.1111/hepr.12461. 
PubMed PMID: 26205698.

7: Mizuno S, Hirano K, Isayama H, Watanabe T, Yamamoto N, Nakai Y, Sasahira N, 
Tada M, Omata M, Koike K. Prospective study of bezafibrate for the treatment of 
primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2015 
Oct;22(10):766-70. doi: 10.1002/jhbp.281. Epub 2015 Aug 21. PubMed PMID: 
26173026.

8: Licinio R, Facciorusso A, Castellaneta NM, Di Leo A. Combination Therapy of 
Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: 
The End of the Steroid Era in Autoimmune Liver Diseases? Am J Gastroenterol. 2015 
Jul;110(7):1086. doi: 10.1038/ajg.2015.163. PubMed PMID: 26148263.

9: Djouadi F, Habarou F, Le Bachelier C, Ferdinandusse S, Schlemmer D, Benoist 
JF, Boutron A, Andresen BS, Visser G, de Lonlay P, Olpin S, Fukao T, Yamaguchi S, 
Strauss AW, Wanders RJ, Bastin J. Mitochondrial trifunctional protein deficiency 
in human cultured fibroblasts: effects of bezafibrate. J Inherit Metab Dis. 2015 
Jun 25. [Epub ahead of print] PubMed PMID: 26109258.

10: Kobayashi J. How Does Bezafibrate Affect the Plasma LDL Cholesterol Levels? J 
Atheroscler Thromb. 2015 Jul 23;22(7):658-9. doi: 10.5551/jat.ED007. Epub 2015 
Mar 6. PubMed PMID: 25752495.

11: Hirose T, Teramoto T, Abe K, Taneyama T; J-BENEFIT study group. Determinants 
of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients 
with Diabetes. J Atheroscler Thromb. 2015 Jul 23;22(7):676-84. doi: 
10.5551/jat.27425. Epub 2015 Mar 6. PubMed PMID: 25752494.

12: Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Horiguchi N, 
Kakizaki S, Kusano M, Yamada M. A prospective randomized controlled study of 
long-term combination therapy using ursodeoxycholic acid and bezafibrate in 
patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 
2015 Mar;110(3):423-31. doi: 10.1038/ajg.2015.20. Epub 2015 Mar 3. PubMed PMID: 
25732417.

13: Saha L, Bhandari S, Bhatia A, Banerjee D, Chakrabarti A. Anti-kindling Effect 
of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in 
Pentylenetetrazole Induced Kindling Seizure Model. J Epilepsy Res. 2014 Dec 
31;4(2):45-54. eCollection 2014 Dec. PubMed PMID: 25625088; PubMed Central PMCID: 
PMC4295053.

14: Vatanavicharn N, Yamada K, Aoyama Y, Fukao T, Densupsoontorn N, Jirapinyo P, 
Sathienkijkanchai A, Yamaguchi S, Wasant P. Carnitine-acylcarnitine translocase 
deficiency: Two neonatal cases with common splicing mutation and in vitro 
bezafibrate response. Brain Dev. 2015 Aug;37(7):698-703. doi: 
10.1016/j.braindev.2014.10.005. Epub 2014 Nov 1. PubMed PMID: 25459972.

15: Shiochi H, Ohkura T, Fujioka Y, Sumi K, Yamamoto N, Nakanishi R, Matsuzawa K, 
Izawa S, Ohkura H, Inoue K, Ueta E, Kato M, Taniguchi S, Yamamoto K. Bezafibrate 
improves insulin resistance evaluated using the glucose clamp technique in 
patients with type 2 diabetes mellitus: a small-scale clinical study. Diabetol 
Metab Syndr. 2014 Oct 17;6(1):113. doi: 10.1186/1758-5996-6-113. eCollection 
2014. PubMed PMID: 25360162; PubMed Central PMCID: PMC4213459.

16: Ørngreen MC, Vissing J, Laforét P. No effect of bezafibrate in patients with 
CPTII and VLCAD deficiencies. J Inherit Metab Dis. 2015 Mar;38(2):373-4. doi: 
10.1007/s10545-014-9779-3. Epub 2014 Oct 21. PubMed PMID: 25331908.

17: Bastin J, Bonnefont JP, Djouadi F, Bresson JL. Should the beneficial impact 
of bezafibrate on fatty acid oxidation disorders be questioned? J Inherit Metab 
Dis. 2015 Mar;38(2):371-2. doi: 10.1007/s10545-014-9775-7. Epub 2014 Oct 14. 
PubMed PMID: 25310995.

18: Tanaka A, Hirohara J, Nakanuma Y, Tsubouchi H, Takikawa H. Biochemical 
responses to bezafibrate improve long-term outcome in asymptomatic patients with 
primary biliary cirrhosis refractory to UDCA. J Gastroenterol. 2015 
Jun;50(6):675-82. doi: 10.1007/s00535-014-0998-z. Epub 2014 Sep 20. PubMed PMID: 
25239675.

19: Shioya A, Takuma H, Yamaguchi S, Ishii A, Hiroki M, Fukuda T, Sugie H, 
Shigematsu Y, Tamaoka A. Amelioration of acylcarnitine profile using bezafibrate 
and riboflavin in a case of adult-onset glutaric acidemia type 2 with novel 
mutations of the electron transfer flavoprotein dehydrogenase (ETFDH) gene. J 
Neurol Sci. 2014 Nov 15;346(1-2):350-2. doi: 10.1016/j.jns.2014.08.040. Epub 2014 
Aug 30. PubMed PMID: 25216552.

20: Gonçalves AG, Órfão JJ, Pereira MF. Ozonation of bezafibrate over ceria and 
ceria supported on carbon materials. Environ Technol. 2015 
Mar-Apr;36(5-8):776-85. doi: 10.1080/09593330.2014.961563. Epub 2014 Oct 3. 
PubMed PMID: 25189707.